Nephrocare Health Services Ltd
Nephrocare Health Services Ltd (NEPHROPLUS) last traded at ₹700, a market capitalisation of ₹7,044 crore, on a P/E of 82.7. Over the past 52 weeks the stock has ranged between ₹445 and ₹770. Nephrocare Health Services Ltd last reported results for the quarter ended Jun 2026, with sales of ₹282 crore and net profit of ₹32 crore. Figures are as of 25 Aug 2026 and are not real time.
Nephrocare Health Services Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Nephrocare Health Services Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹282 cr, up 23.7% from ₹228 cr a year earlier. Net profit was ₹32 cr, up 33.3% year on year.
| ₹ crore | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 197 | 219 | 228 | 246 | 260 | 266 | 282 |
| Expenses | 153 | 168 | 180 | 182 | 199 | 215 | 221 |
| Operating profit | 44 | 51 | 48 | 64 | 61 | 51 | 60 |
| OPM % | 22% | 23% | 21% | 26% | 23% | 19% | 21% |
| Other income | 5 | 4 | 7 | 4 | 3 | 12 | 7 |
| Interest | 5 | 6 | 6 | 45 | 6 | 3 | 2 |
| Depreciation | 18 | 19 | 20 | 23 | 22 | 26 | 25 |
| Profit before tax | 26 | 30 | 29 | -1 | 36 | 33 | 41 |
| Tax % | 24% | 17% | 17% | 1,427% | 11% | 9% | 22% |
| Net profit | 20 | 25 | 24 | -9 | 32 | 30 | 32 |
| EPS (₹) | 96.50 | 119.30 | 13.10 | -5.24 | 3.21 | 3.03 | 3.19 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Nephrocare Health Services Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 286 | 318 | 437 | 566 | 756 | 999 | 1,053 |
| Operating profit | 37 | 16 | 49 | 101 | 167 | 225 | 236 |
| OPM % | 13% | 5% | 11% | 18% | 22% | 23% | 22% |
| Net profit | 1 | -21 | -12 | 35 | 67 | 77 | 85 |
| EPS (₹) | 3.40 | -106.93 | -58.69 | 169.82 | 321.87 | 7.66 | 4.19 |
TTM is the trailing twelve months to the most recent quarter.
Nephrocare Health Services Ltd growth and returns
- 10 Years
- %
- 5 Years
- 28%
- 3 Years
- 32%
- TTM
- 32%
- 10 Years
- %
- 5 Years
- 162%
- 3 Years
- 103%
- TTM
- 12%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- %
- 10 Years
- %
- 5 Years
- 6%
- 3 Years
- 10%
- Last Year
- 9%
Nephrocare Health Services Ltd shareholding pattern
Promoters held 63.85% at Jun 2026, broadly unchanged since Dec 2025. FIIs 8.78% and DIIs 9.05%.
| % held | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|
| Promoters | 63.85% | 63.85% | 63.85% |
| FIIs | 9.30% | 9.94% | 8.78% |
| DIIs | 8.10% | 8.64% | 9.05% |
| Public | 18.74% | 17.56% | 18.30% |
| No. of shareholders | 67,416 | 43,409 | 44,091 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Nephrocare Health Services Ltd corporate filings
- Announcement under Regulation 30 (LODR)-Earnings Call TranscriptCompany Updatehigh impact
Cruxal's analysis: Nephrocare Health Services Limited reported a robust Q1 FY27 performance with revenue…
Read the full analysis - Pursuant to Reg 30 of SEBI Listing Regulations, we hereby inform that Nephrocare Health Services, Phillipines Inc., a step-down wholly-owned subsidiary of the Company has acquired a dialysis ....Company Updatemedium impact
Cruxal's analysis: Nephrocare Health Services, Philippines Inc., a step-down wholly-owned subsidiary, has…
Read the full analysis - Declartion of voting results along with scrutinizers report of the 17th AGM of the Company.AGM/EGMlow impact
Cruxal's analysis: Nephrocare Health Services Limited has successfully concluded its 17th Annual General…
Read the full analysis - Pursuant to Reg 30 of the SEBI Listing Regulations, we hereby inform you that the Company has scheduled an investor conference call as per the disclosure annexed herewith.Company Updatelow impact
Cruxal's analysis: Nephrocare Health Services Ltd has issued a formal intimation under Regulation 30 of the…
Read the full analysis - Pursuant to Reg 30 of SEBI Listing Regulations, we hereby inform that Nephrocare Health Services, Phillipines Inc., an overseas stepdown wholly-owned subsidiary of the Company has acquired ....Company Updatemedium impact
Cruxal's analysis: Nephrocare Health Services, Philippines Inc., a stepdown wholly-owned subsidiary, has…
Read the full analysis - Clarification to disclosure under Reg 30 dated May 26, 2026 regarding incorporation of Nephrocare Services Kazakhstan LLP.Company Updatelow impact
Cruxal's analysis: Nephrocare Health Services Limited has issued a formal clarification regarding the…
Read the full analysis - Summary of proceedings of the 17th AGM of the Company.AGM/EGMlow impact
Cruxal's analysis: Nephrocare Health Services Limited has successfully concluded its 17th Annual General…
Read the full analysis - In Continuation to our letter dated July 24, 2026 please find enclosed link of the audio recording of the Investors'' Conference Call held on August 12, 2026 on the Unaudited Standalone ....Company Updatelow impact
Cruxal's analysis: Nephrocare Health Services Limited has formally submitted the audio recording of its…
Read the full analysis - Pursuant to Reg 32 of SEBI Listing Regulations, read with Reg 41 of SEBI ICDR Regulations, please find enclosed herewith Monitoring Agency Report for quarter ended June 30, 2026.Company Updatelow impact
Cruxal's analysis: Nephrocare Health Services Ltd has submitted its Monitoring Agency Report for the quarter…
Read the full analysis - Press release on Un-audited standalone and consolidated financial results for the quarter ended June 30, 2026.Company Updatehigh impact
Cruxal's analysis: Nephrocare Health Services Limited (NephroPlus) delivered a robust performance for…
Read the full analysis - Announcement under Regulation 30 (LODR)-Investor PresentationCompany Updatehigh impact
Cruxal's analysis: Nephrocare Health Services Limited (NephroPlus) reported robust Q1 FY27 results, with…
Read the full analysis - Un-audited standalone and consolidated financial results for the quarter ended June 30, 2026.Resulthigh impact
Cruxal's analysis: Nephrocare Health Services Limited reported robust consolidated financial results for the…
Read the full analysis - Pursuant to Regulation 30 of SEBI Listing Regulations, we hereby inform you that the Company has scheduled an Investor Conference Call as per the disclosure enclosed herewith.Company Updatelow impact
Cruxal's analysis: Nephrocare Health Services Ltd has announced an investor conference call pursuant to…
Read the full analysis - Announcement under Regulation 30 (LODR)-Trading Plan under SEBI (PIT) Regulations, 2015Company Updatelow impact
Cruxal's analysis: Nephrocare Health Services Ltd has announced that the company's compliance officer has…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Nephrocare Health Services Ltd
Cruxal reads every Nephrocare Health Services Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.